학술논문


EBSCO Discovery Service
발행년
-
(예 : 2010-2015)
전자자료 공정이용 안내

우리 대학 도서관에서 구독·제공하는 모든 전자자료(데이터베이스, 전자저널, 전자책 등)는 국내외 저작권법과 출판사와의 라이선스 계약에 따라 엄격하게 보호를 받고 있습니다.
전자자료의 비정상적 이용은 출판사로부터의 경고, 서비스 차단, 손해배상 청구 등 학교 전체에 심각한 불이익을 초래할 수 있으므로, 아래의 공정이용 지침을 반드시 준수해 주시기 바랍니다.

공정이용 지침
  • 전자자료는 개인의 학습·교육·연구 목적의 비영리적 사용에 한하여 이용할 수 있습니다.
  • 합리적인 수준의 다운로드 및 출력만 허용됩니다. (일반적으로 동일 PC에서 동일 출판사의 논문을 1일 30건 이하 다운로드할 것을 권장하며, 출판사별 기준에 따라 다를 수 있습니다.)
  • 출판사에서 제공한 논문의 URL을 수업 관련 웹사이트에 게재할 수 있으나, 출판사 원문 파일 자체를 복제·배포해서는 안 됩니다.
  • 본인의 ID/PW를 타인에게 제공하지 말고, 도용되지 않도록 철저히 관리해 주시기 바랍니다.
불공정 이용 사례
  • 전자적·기계적 수단(다운로딩 프로그램, 웹 크롤러, 로봇, 매크로, RPA 등)을 이용한 대량 다운로드
  • 동일 컴퓨터 또는 동일 IP에서 단시간 내 다수의 원문을 집중적으로 다운로드하거나, 전권(whole issue) 다운로드
  • 저장·출력한 자료를 타인에게 배포하거나 개인 블로그·웹하드 등에 업로드
  • 상업적·영리적 목적으로 자료를 전송·복제·활용
  • ID/PW를 타인에게 양도하거나 타인 계정을 도용하여 이용
  • EndNote, Mendeley 등 서지관리 프로그램의 Find Full Text 기능을 이용한 대량 다운로드
  • 출판사 콘텐츠를 생성형 AI 시스템에서 활용하는 행위(업로드, 개발, 학습, 프로그래밍, 개선 또는 강화 등)
위반 시 제재
  • 출판사에 의한 해당 IP 또는 기관 전체 접속 차단
  • 출판사 배상 요구 시 위반자 개인이 배상 책임 부담
'학술논문' 에서 검색결과 53건 | 목록 1~20
Academic Journal
Creus-Bachiller E; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Fernández-Rodríguez J; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Mouse Lab, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Magallón-Lorenz M; Hereditary Cancer Group, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain.; Ortega-Bertran S; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Navas-Rutete S; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Romagosa C; Department of Pathology, Hospital Vall d'Hebron, Barcelona, Spain.; Silva TM; Department of Pathology, Hospital Vall d'Hebron, Barcelona, Spain.; Pané M; Department of Pathology, HUB-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Estival A; Department of Medical Oncology, Catalan Institute of Oncology, Barcelona, Spain.; Perez Sidelnikova D; Plastic Surgery Service HUB-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Morell M; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Mouse Lab, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Mazuelas H; Hereditary Cancer Group, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain.; Carrió M; Hereditary Cancer Group, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain.; Lausová T; Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.; Reuss D; Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.; Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.; Gel B; Hereditary Cancer Group, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain.; Villanueva A; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Procure Program, Catalan Institute of Oncology, Barcelona, Spain.; Serra E; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Hereditary Cancer Group, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain.; Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE
Periodical
Marcoval J; Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, Barcelona, Spain.; Moreno-Vílchez C; Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, Barcelona, Spain.; Torrecilla-Vall-Llosera C; Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, Barcelona, Spain.; Muntaner-Virgili C; Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, Barcelona, Spain.; Pérez Sidelnikova D; Department of Plastic Surgery, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, Barcelona, Spain.; Sanjuán X; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, Barcelona, Spain.; Penín RM; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
Publisher: Karger Country of Publication: Switzerland NLM ID: 9203244 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1421-9832 (Electronic) Linking ISSN: 10188665 NLM ISO Abbreviation: Dermatology Subsets: MEDLINE
Academic Journal
Magallón-Lorenz M; Hereditary Cancer Group, Germans Trias i Pujol Research Institute (IGTP)-PMPPC, Badalona, 08916, Barcelona, Spain.; Fernández-Rodríguez J; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (ONCOBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.; Terribas E; Hereditary Cancer Group, Germans Trias i Pujol Research Institute (IGTP)-PMPPC, Badalona, 08916, Barcelona, Spain.; Oncohematology Area, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Illes Balears, Spain.; Creus-Batchiller E; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (ONCOBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.; Romagosa C; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.; Pathology Department, Hospital Universitari Vall d'Hebron and Vall d'Hebron Research Institut (VHIR), 08035, Barcelona, Spain.; Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain.; Estival A; B-ARGO Group, Catalan Institute of Oncology - Hospital Universitari Germans Tries i Pujol, Badalona, 08916, Barcelona, Spain.; Perez Sidelnikova D; Plastic Surgery Service, Functional Sarcoma Unit, ICO-HUB, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.; Salvador H; Pediatric Oncology Department, Sant Joan de Déu Barcelona Children's Hospital, 08950, Barcelona, Spain.; Villanueva A; Program in Molecular Mechanisms and Experimental Therapy in Oncology (ONCOBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Spain.; Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO-IDIBELL, L'Hospitalet del Llobregat, 08908, Barcelona, Spain.; Blanco I; Programa d'Assessorament i Genètica Clínica, Hospital Universitari Germans Trias i Pujol, Badalona, 08916, Barcelona, Spain.; Carrió M; Hereditary Cancer Group, Germans Trias i Pujol Research Institute (IGTP)-PMPPC, Badalona, 08916, Barcelona, Spain.; Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Spain.; Program in Molecular Mechanisms and Experimental Therapy in Oncology (ONCOBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain.; Serra E; Hereditary Cancer Group, Germans Trias i Pujol Research Institute (IGTP)-PMPPC, Badalona, 08916, Barcelona, Spain. eserra@igtp.cat.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Barcelona, Spain. eserra@igtp.cat.; Gel B; Hereditary Cancer Group, Germans Trias i Pujol Research Institute (IGTP)-PMPPC, Badalona, 08916, Barcelona, Spain. bgel@igtp.cat.; Departament de Fonaments Clínics, Universitat de Barcelona, 08036, Barcelona, Spain. bgel@igtp.cat.
Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7613873 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1203 (Electronic) Linking ISSN: 03406717 NLM ISO Abbreviation: Hum Genet Subsets: MEDLINE
Academic Journal
Castellsagué J; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain Translational Research Laboratory ICO-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Gel B; Institut de Medicina Predictiva i Personalitzada del Càncer (IMPPC), Badalona, Barcelona, Spain.; Fernández-Rodríguez J; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain Translational Research Laboratory ICO-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Llatjós R; Pathology Service, HUB-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Blanco I; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Benavente Y; Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Program ICO-IDIBELL and CIBER Epidemiología y Salud Pública (CIBERESP), L'Hospitalet de Llobregat, Barcelona, Spain.; Pérez-Sidelnikova D; Plastic Surgery Service HUB-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; García-Del Muro J; Medical Oncology Service ICO-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Viñals JM; Plastic Surgery Service HUB-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Vidal A; Pathology Service, HUB-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Valdés-Mas R; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, Oviedo, Spain.; Terribas E; Institut de Medicina Predictiva i Personalitzada del Càncer (IMPPC), Badalona, Barcelona, Spain.; López-Doriga A; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain Translational Research Laboratory ICO-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Pujana MA; Translational Research Laboratory ICO-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain Translational Research Laboratory ICO-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.; Puente XS; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, Oviedo, Spain.; Serra E; Institut de Medicina Predictiva i Personalitzada del Càncer (IMPPC), Badalona, Barcelona, Spain clazaro@iconcologia.net avillanueva@iconcologia.net eserra@imppc.org.; Villanueva A; Translational Research Laboratory ICO-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain clazaro@iconcologia.net avillanueva@iconcologia.net eserra@imppc.org.; Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain Translational Research Laboratory ICO-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain clazaro@iconcologia.net avillanueva@iconcologia.net eserra@imppc.org.
Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE
Academic Journal
Bernat-Peguera A; Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Navarro-Ventura J; Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Lorenzo-Sanz L; Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; da Silva-Diz V; Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Bosio M; Department of Life Sciences, Barcelona Supercomputing Center (BSC), Barcelona, Spain.; Palomero L; Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, Barcelona, Spain.; Penin RM; Pathology Service, Hospital Universitario de Bellvitge/IDIBELL, Barcelona, Spain.; Pérez Sidelnikova D; Plastic Surgery Unit, Hospital Universitario de Bellvitge/IDIBELL, Barcelona, Spain.; Bermejo JO; Plastic Surgery Unit, Hospital Universitario de Bellvitge/IDIBELL, Barcelona, Spain.; Taberna M; Department of Medical Oncology, Oncobell Program, IDIBELL, ICO, Barcelona, Spain.; Vilariño N; Department of Medical Oncology, Oncobell Program, IDIBELL, ICO, Barcelona, Spain.; Piulats JM; Department of Medical Oncology, Oncobell Program, IDIBELL, ICO, Barcelona, Spain.; Mesia R; Department of Medical Oncology, ICO, B-ARGO Group-Badalona, IGTP, Barcelona, Spain.; Viñals JM; Plastic Surgery Unit, Hospital Universitario de Bellvitge/IDIBELL, Barcelona, Spain.; González-Suárez E; Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Molecular Oncology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Capella-Gutierrez S; Department of Life Sciences, Barcelona Supercomputing Center (BSC), Barcelona, Spain.; Villanueva A; Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, Barcelona, Spain.; Viñals F; Program Against Cancer Therapeutic Resistance (ProCURE), ICO, IDIBELL, Barcelona, Spain.; Unitat de Bioquímica i Biologia Molecular, Departament de Ciències Fisiològiques, Universitat de Barcelona-IDIBELL, Barcelona, Spain.; Muñoz P; Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. p.munoz@idibell.cat.
Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Academic Journal
Viñls Viñals JM; Departamento de Cirugía Plástica, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. jm.vinals@bellvitgehospital.cat; Pérez Sidelnikova DSerra Payro JMPalacín Porte JALópez Ojeda ABHigueras Suñe MCGarcía del Muro JLozano Borbalas APortabella Blavia FSanjuán Garriga FJNarváez García JA
Publisher: Springer Italia Country of Publication: Italy NLM ID: 101247119 Publication Model: Print Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE
Academic Journal
Bernat-Peguera A; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Simón-Extremera P; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; da Silva-Diz V; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA.; López de Munain M; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Díaz-Gil L; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Penin RM; Pathology Service, Hospital Universitario de Bellvitge/IDIBELL, Barcelona, Spain.; González-Suárez E; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; Pérez Sidelnikova D; Plastic Surgery Unit, Hospital Universitario de Bellvitge/IDIBELL, Barcelona, Spain.; Bermejo O; Plastic Surgery Unit, Hospital Universitario de Bellvitge/IDIBELL, Barcelona, Spain.; Viñals JM; Plastic Surgery Unit, Hospital Universitario de Bellvitge/IDIBELL, Barcelona, Spain.; Viñals F; Laboratory of Translational Research, Catalan Institute of Oncology (ICO/IDIBELL), Barcelona, Spain.; Unitat de Bioquímica i Biologia Molecular, Departament de Ciències Fisiològiques, Universitat de Barcelona-IDIBELL, Barcelona, Spain.; Muñoz P; Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. p.munoz@idibell.cat.
Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE
검색 결과 제한하기
제한된 항목
[검색어] Sidelnikova, D. Perez
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어